Ultragenyx [RARE] vs Axsome Therapeutics [AXSM] Detailed Stock Comparison

Ultragenyx Pharmaceutical Inc.

NASDAQ
Loading...

Axsome Therapeutics Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 19 vital metrics comparison: Ultragenyx Pharmaceutical Inc. wins in 6 metrics, Axsome Therapeutics Inc. wins in 13 metrics, with 0 ties. Axsome Therapeutics Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Ultragenyx Pharmaceutical Inc. Axsome Therapeutics Inc. Better
P/E Ratio (TTM) -4.13 -50.54 Ultragenyx Pharmaceutical Inc.
Price-to-Book Ratio -32.98 105.31 Axsome Therapeutics Inc.
Debt-to-Equity Ratio -17.15 247.03 Axsome Therapeutics Inc.
PEG Ratio 0.57 0.79 Ultragenyx Pharmaceutical Inc.
EV/EBITDA -5.81 -57.70 Ultragenyx Pharmaceutical Inc.
Profit Margin (TTM) -85.44% -28.69% Axsome Therapeutics Inc.
Operating Margin (TTM) -54.65% -18.38% Axsome Therapeutics Inc.
Return on Equity -608.47% -252.12% Axsome Therapeutics Inc.
Return on Assets (TTM) -22.04% -16.81% Axsome Therapeutics Inc.
Free Cash Flow (TTM) $-487.00M $-93.89M Axsome Therapeutics Inc.
1-Year Return -29.65% 122.97% Axsome Therapeutics Inc.
Price-to-Sales Ratio (TTM) 3.52 14.64 Ultragenyx Pharmaceutical Inc.
Enterprise Value $2.90B $9.24B Axsome Therapeutics Inc.
EV/Revenue Ratio 4.31 14.47 Ultragenyx Pharmaceutical Inc.
Gross Profit Margin (TTM) 85.84% 93.71% Axsome Therapeutics Inc.
Revenue per Share (TTM) $7 $13 Axsome Therapeutics Inc.
Earnings per Share (Diluted) $-5.83 $-3.69 Axsome Therapeutics Inc.
Beta (Stock Volatility) 0.25 0.47 Ultragenyx Pharmaceutical Inc.
Short % of Float 12.72% 6.56% Axsome Therapeutics Inc.

Ultragenyx Pharmaceutical Inc. vs Axsome Therapeutics Inc. Stock Performance Analysis

Loading Price Chart...

RARE
AXSM

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Ultragenyx Pharmaceutical Inc.2.89%-5.88%-12.21%-5.39%-34.93%-7.71%
Axsome Therapeutics Inc.5.09%-5.14%-0.69%33.53%56.35%24.33%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Ultragenyx Pharmaceutical Inc.-29.65%-52.92%-74.03%-65.57%-43.34%-43.34%
Axsome Therapeutics Inc.122.97%216.35%282.39%2,961.10%2,485.23%2,485.23%

Performance & Financial Health Analysis: Ultragenyx Pharmaceutical Inc. vs Axsome Therapeutics Inc.

MetricRAREAXSM
Market Information
Market Cap i$2.37B$9.51B
Market Cap CategoryMid capMid cap
10 Day Avg. Volume i1,596,080592,425
90 Day Avg. Volume i1,981,590602,162
Last Close$22.41$233.47
52 Week Range$18.29 - $42.37$96.09 - $238.56
% from 52W High-47.11%-2.13%
All-Time High$179.65 (Dec 21, 2020)$238.56 (May 26, 2026)
% from All-Time High-87.53%-2.13%
Growth Metrics
Quarterly Revenue Growth0.26%0.65%
Quarterly Earnings Growth0.26%0.65%
Financial Health
Profit Margin (TTM) i-0.85%-0.29%
Operating Margin (TTM) i-0.55%-0.18%
Return on Equity (TTM) i-6.08%-2.52%
Debt to Equity (MRQ) i-17.15247.03
Cash & Liquidity
Book Value per Share (MRQ)$-0.83$1.74
Cash per Share (MRQ)$7.05$6.31
Operating Cash Flow (TTM) i$-466,000,000$-93,405,000
Levered Free Cash Flow (TTM) i$-251,124,992$-29,420,876
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Ultragenyx Pharmaceutical Inc. vs Axsome Therapeutics Inc.

MetricRARE (Apr 26, 2026)AXSM (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) i-4.13-50.54
Forward P/E i-1,893.1729.85
PEG Ratio i0.570.79
Price to Sales (TTM) i3.5214.64
Price to Book (MRQ) i-32.98105.31
Market Capitalization
Market Capitalization i$2.37B$9.51B
Enterprise Value i$2.90B$9.24B
Enterprise Value Metrics
Enterprise to Revenue i4.3114.47
Enterprise to EBITDA i-5.81-57.70
Risk & Other Metrics
Beta i0.250.47
Book Value per Share (MRQ) i$-0.83$1.74

Financial Statements Comparison: Ultragenyx Pharmaceutical Inc. vs Axsome Therapeutics Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricRARE (2025)AXSM (2025)
Revenue/Sales i673.00M638.50M
Cost of Goods Sold i109.00M47.48M
COGS % of Revenue i16.2%7.4%
Gross Profit i564.00M591.02M
Gross Margin i83.8%92.6%
Research & Development i750.00M183.28M
Operating Income (EBIT) i-535.00M-169.24M
Operating Margin i-79.5%-26.5%
EBITDA i-474.00M-160.17M
EBITDA Margin i-70.4%-25.1%
Pre-Tax Income i-571.00M-183.70M
Pre-Tax Income % of Revenue i-84.8%-28.8%
Income Tax i4.00M-530,000
Income Tax % of Revenue i0.6%-0.1%
Net Income (Profit) i-575.00M-183.17M
Profit Margin i-85.4%-28.7%

Balance Sheet & Liquidity Metrics

MetricRARE (2025)AXSM (2025)
Cash & Equivalents i421.00M322.93M
Total Current Assets i951.00M588.99M
Total Current Assets % of Revenue i141.3%92.2%
Total Current Liabilities i384.00M378.84M
Total Current Liabilities % of Revenue i57.1%59.3%
Long-Term Debt i24.00M145.13M
Long-Term Debt % of Revenue i3.6%22.7%
Total Shareholders Equity i-73.00M88.30M
Retained Earnings i-4.53B-1.31B
Retained Earnings % of Revenue i-673.4%-204.5%
Property, Plant & Equipment i0562,000

Cash Flow Statement Comparison

MetricRARE (2025)AXSM (2025)
Operating Cash Flow i-452.00M-185.86M
Operating Cash Flow % of Revenue i-67.2%-29.1%
Capital Expenditures i-6.00M-480,000
Free Cash Flow i-487.00M-93.89M
FCF Margin i-72.4%-14.7%
Debt Repayment iN/A-334.11M
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricRAREAXSM
Shares Short i12.09M2.83M
Short Ratio i5.764.92
Short % of Float i12.72%6.56%
Shares Outstanding i96.48M50.88M
Float Shares i92.93M43.24M
% Held by Insiders i3.42%15.47%
% Held by Institutions i100.75%76.52%
% Held by Public i-4.17%8.01%

Dividend Analysis & Yield Comparison: Ultragenyx Pharmaceutical Inc. vs Axsome Therapeutics Inc.

MetricRAREAXSM
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A